rybrevant
janssen-cilag international n.v. - amivantamab - karzinom, nicht kleinzellige lunge - antineoplastische mittel - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.
chirocaine 1.25 mg/ml inf. sol. epidur.
chirocaine 1.25 mg/ml inf. opl. epidur.
levobupivacaïne altan pharma 1.25 mg/ml inf. sol. epidur.
levobupivacaïne altan pharma 1.25 mg/ml inf. opl. epidur.
ropivacain hcl noridem 2 mg/ml inf. sol. epidur.
ropivacain hcl noridem 2 mg/ml inf. opl. epidur.
ropivacain hcl noridem 2 mg/ml inf. sol. epidur. vial
ropivacain hcl noridem 2 mg/ml inf. opl. epidur. flac.
ropivacaine fresenius kabi 2 mg/ml inj. sol. epidur. amp.